Low-dose chemo to prevent relapse in high-risk DLBCL patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of DLBCL called 'double-expressor lymphoma' (high MYC and BCL2 proteins).
- You must be in complete remission after your first round of chemotherapy.
- You must have a positive blood test for minimal residual disease (MRD), meaning tiny traces of cancer DNA are still detectable.
- You must be between 18 and 80 years old.
- You must have an ECOG performance status of 0, 1, or 2 (able to care for yourself up to mostly bedridden).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.